Arch Therapeutics (ARTH) Lifted to “Buy” at Zacks Investment Research

Arch Therapeutics (OTCMKTS:ARTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $0.50 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 49.25% from the stock’s previous close.

According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “

How to Become a New Pot Stock Millionaire

A number of other equities analysts have also commented on ARTH. ValuEngine lowered shares of Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 19th. Finally, Ifs Securities raised shares of Arch Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $2.17.

Arch Therapeutics (ARTH) opened at $0.34 on Thursday. Arch Therapeutics has a 52 week low of $0.25 and a 52 week high of $0.89. The company has a market cap of $52.38, a P/E ratio of -8.38 and a beta of 0.52.

WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/03/10/arch-therapeutics-arth-lifted-to-buy-at-zacks-investment-research.html.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply